榄香烯注射液联合一线化疗方案治疗非小细胞肺癌的疗效及安全性  

Efficacy and safety of elemene injection combined with first-line chemotherapy regimen in the treatment of non-small cell lung cancer

作　　者：张细红 何燕华 邱卫璠 邹方友 王莉萍[1] ZHANG Xihong;HE Yanhua;QIU Weifan;ZOU Fangyou;WANG Liping(Department of Clinical Pharmacy,First People’s Hospital of Fuzhou,Fuzhou 344000,Jiangxi,China;Department of Pharmacy,First People’s Hospital of Fuzhou,Fuzhou 344000,Jiangxi,China)

机构地区：[1]抚州市第一人民医院临床药学室,江西抚州3440000 [2]抚州市第一人民医院药剂科,江西抚州3440000

出　　处：《癌症进展》2024年第17期1896-1899,共4页Oncology Progress

基　　金：江西省卫生健康委科技计划项目(202140806)。

摘　　要：目的探讨榄香烯注射液联合吉西他滨+顺铂(一线化疗方案)治疗非小细胞肺癌(NSCLC)的疗效及安全性。方法根据治疗方法的不同将78例NSCLC患者分为观察组和对照组,每组39例,对照组患者接受吉西他滨+顺铂治疗,观察组患者在对照组的基础上联合榄香烯注射液治疗。比较两组患者的临床疗效、免疫功能指标[CD3^(+)、自然杀伤(NK)细胞、CD4^(+)/CD8^(+)]、生活质量[卡氏功能状态(KPS)评分]及不良反应发生情况。结果观察组患者的总有效率高于对照组,差异有统计学意义(P﹤0.05)。治疗后,两组患者CD3^(+)、NK细胞、CD4^(+)/CD8^(+)均低于本组治疗前,KPS评分均高于本组治疗前,观察组患者CD3^(+)、NK细胞、CD4^(+)/CD8^(+)、KPS评分均高于对照组,差异均有统计学意义(P﹤0.05)。两组患者各不良反应发生率比较,差异均无统计学意义(P﹥0.05)。结论榄香烯注射液联合吉西他滨+顺铂治疗NSCLC患者,可提高治疗效果、免疫功能及生活质量,并且不会增加不良反应。Objective To investigate the efficacy and safety of elemene injection combined with gemcitabine+cisplatin(first-line chemotherapy regimen)in the treatment of non-small cell lung cancer(NSCLC).Method A total of 78 patients with NSCLC were divided into observation group and control group according to different treatment methods,with 39 cases in each group.The control group received gemcitabine+cisplatin treatment,and the observation group received elemene injection treatment on the basis of the control group.The clinical efficacy,immune function indicators[CD3^(+),natural killer(NK)cell,CD4^(+)/CD8^(+)],quality of life[Karnofsky performance status(KPS)score]and the incidence of adverse reactions were compared between the two groups.Result The total effective rate of observation group was higher than that of control group,and the difference was statistically significant(P<0.05).After treatment,the CD3^(+),NK cells and CD4^(+)/CD8^(+)in two groups were lower than those before treatment,the KPS scores were higher than those before treatment,the CD3^(+),NK cell,CD4^(+)/CD8^(+)and KPS score in observation group were higher than those in control group,and the differences were statistically significant(P<0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Elemene injection combined with gemcitabine+cisplatin in the treatment of NSCLC patients can improve the therapeutic effect,immune function and quality of life,without increasing adverse reactions.

关 键 词：非小细胞肺癌 榄香烯注射液 吉西他滨 顺铂 疗效 安全性 

分 类 号：R734.2[医药卫生—肿瘤]